- Home
- CISS vs ADXN Comparison
CISS vs ADXN Comparison
Compare CISS & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | ADXN |
|---|---|---|
| Founded | 2022 | 2002 |
| Country | Greece | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 991.9K | 10.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CISS | ADXN |
|---|---|---|
| Price | $1.82 | $7.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 273.5K | 8.4K |
| Earning Date | 03-10-2026 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,613,149.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.63 | $6.51 |
| 52 Week High | $154.79 | $12.05 |
Technical Indicators
Market Signals| Indicator | CISS | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 76.67 | 48.56 |
| Support Level | $0.08 | $7.63 |
| Resistance Level | $2.50 | $8.49 |
| Average True Range (ATR) | 0.10 | 0.57 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 71.46 | 28.57 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.